Table 1.
Percentuals of answers to the proposed questions
| ANSWERES' PERCENTAGES | |||
|---|---|---|---|
| PROPOSED QUESTIONS | Yes | No | Others |
| 1. Have you read the Treatment of Type 2 Diabetes algorithm proposed by ADA/EASD? | 90 | 10 | - |
| 2. Were you aware that the document expresses the opinion of a few authors and not of the entities involved? | 77 | 23 | - |
| 3. Do you intend to adopt the stages and steps suggested by this algorithm in your practice? | 51 | 49 | - |
| 4. Do you think that rosiglitazone-associated adverse events have been ratified in the medical literature of excellence? | 36 | 64 | - |
| 5. Do you think that the cardiovascular protection assigned topioglitazone in that Position Statement is real? | 34 | 66 | - |
| 6. Do you think that glitazone-associated adverse events (bone fracture and cardiovascular events) are effects pertaining to this therapeutical class? | 49 | 21 | 30 |
| 7. Do you think that only GLP-1 analogs should be included in diabetes treatment excluding DPP-4 inhibitors? | 13 | 69 | 18 |
| 8. Do you think that BDS' members have the expertise and the ability of criticism to issue a Position Statement about this Algorithm? | 87 | 4 | 9 |
Gomes MB. Enquete sobre Algoritmo ADA/EASD - December 2008 - 217 Sócios da SBD. Available at: http://www.diabetes.org.br/agenda/comunicados/index.php?id=1838. Accessed on: July 13, 2009.